From the publishers of JADPRO

MPN Resource Center

Advertisement

FDA Approves Ropeginterferon Alpha-2b for Polycythemia Vera

The FDA recently approved the monopegylated, long-acting interferon ropeginterferon a-2b-njft for the treatment of patients with polycythemia vera. The approval was based on safety data from the phase 1/2 PEGINVERA trial and the phase 3 CONTINUATION-PV and PROUD-PV trials, and efficacy data from PEGINVERA.

CancerNetwork
Advertisement
News & Literature Highlights
Advertisement
Advertisement